A new working paper has found that one-third of all data points collected in 105 phase 2 and 3 trials were not needed for the studies’ key analyses, while also highlighting how an increase in clinical ...
Arash Yavari - Imbria Pharmaceuticals, Inc. Welcome to Medicenna Therapeutics KOL Webinar. [Operator Instructions] As a reminder, this conference call is being recorded. If you have any objections, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results